Ajanta Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Ajanta Pharma from all sources in a single place.

Ajanta Pharma Ltd.

09 Mar 2026

2904.70

-1.33%

Company Update

Ajanta Pharma Ltd - 532331 - Participation In Investor Conference

BSE India

Pls find enclosed intimation w.r.t Participation in Investor Conference.

pdf

Ajanta Pharma Ltd.

06 Mar 2026

2904.70

-1.33%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 06, 2026 for Aayush Agrawal, Trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

23 Feb 2026

2904.70

-1.33%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 23, 2026 for Aayush Agrawal, Trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

17 Feb 2026

2904.70

-1.33%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 16, 2026 for Aayush Agrawal, Trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

10 Feb 2026

2904.70

-1.33%

Corp. Note

Ajanta Pharma Ltd - 532331 - Rumour verification - Regulation 30(11)

BSE India

Pls find enclosed Clarification on Market Rumour.

pdf

Ajanta Pharma Ltd.

06 Feb 2026

2904.70

-1.33%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 06, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

05 Feb 2026

2904.70

-1.33%

Earnings Call

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Pls find enclosed Earnings Call Transcript

pdf

Ajanta Pharma Ltd.

02 Feb 2026

2904.70

-1.33%

Company Update

Ajanta Pharma Ltd - 532331 - Participation In Investor Conference

BSE India

Pls find enclosed intimation w.r.t Participation in Investor Conference

pdf

Ajanta Pharma Ltd.

02 Feb 2026

2904.70

-1.33%

Company Update

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pls find enclosed newspaper cuttings of Financial results published.

pdf

Ajanta Pharma Ltd.

01 Feb 2026

2904.70

-1.33%

Ajanta Pharma Ltd.

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Branded generics traction, US momentum key differentiators- Branded business growth in India was significantly above the trendline and without one-offs, driven by 16 new launches over the last 9-12 months and improved coverage. The US also maintained the growth tempo on account of 8 new launches over the last 9-12 months and market share gain in the existing products. US traction is contrary to the existing industry trend as the focus remains on specific launches. Africa branded continued to be driven by new launches. Asia branded on the other hand witnessed...

Promoters pledged 2.01% of shares in last quarter. Total pledge stands at 17.29% of promoter holdings

Is Ajanta Pharma Ltd. worth buying?

195 Votes:

Buy 76.92%

Sell 16.41%

Hold 6.67%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf